Making Medicines affordable.
News Room
Latest NewsPress Releases
Releases 2009 Releases 2008 Releases 2007 Releases 2006 Releases 2005 Releases 2004 Releases 2003Media Kit
Handy InfoPress Releases
2007
EGA NEWS: 29 November 2007
Japanese Genereric Pharmaceutical Manufacturers Association Joins IGPAMr Hiroyuki Sawai accepts membership during the 10th Annual IGPA Conference in Miami.
PRESS RELEASE: 21 November 2007
PUBLIC INFORMATION LAUNCHED ON BIOSIMILAR MEDICINES The European Generic medicines Association (EGA) launched its handbook
on biosimilar medicines today in Brussels.
PRESS RELEASE: 21 November 2007
EGA ELECTS ERIC GORKA AS PRESIDENT: FOCUS WILL BE ON SPEEDING NEW MEDICINES TO MARKETThe European Generic medicines Association (EGA) has elected Eric Gorka, Head Commercial Operations EMEA for Sandoz International, as its new president.
PRESS RELEASE: 20 September 2007
EUROPEAN GENERIC MEDICINES INDUSTRY LAUNCHES PACT AGAINST THE COUNTERFEITING OF MEDICINES The European Generic medicines Association (EGA) has today launched a plan to establish a supply chain integrity pact to fight the counterfeiting of pharmaceuticals.
PRESS RELEASE: 3 September 2007
EGA WELCOMES APPROVAL OF FIRST BIOSIMILAR EPOETIN The new biosimilar medicines, based on one development, have been shown to match a previously approved reference product in terms of quality, safety and efficacy...
PRESS RELEASE: 26 June 2007
EGA URGES PRICE DELINKAGE FOR OFF-PATENT MEDICINES AT EU HIGH LEVEL FORUM ON PHARMACEUTICALSSpeaking today at the High Level Forum on Pharmaceuticals, EGA President Emile Loof urged European medicines regulators not to link the price of generic medicines to the price of their corresponding originator products.
PRESS RELEASE: 24 May 2007
3rd EGA SOUTH EAST EUROPE SYMPOSIUM:“Meeting the European Challenge for the National Drug Regulatory Agencies and the Generic Medicines Industry”
Greg Perry praised representatives
from thirteen regional medicines agencies for their commitment to understanding
EU legislation, and cautioned against adopting provisions which could
negativly impact the availability of affordable generic medicines in
the region.
PRESS RELEASE: 14 May 2007
KEEPING COUNTERFEIT MEDICINES OUT OF THE EU: A PROPORTIONAL AND TARGETED APPROACH REQUIREDGreg Perry, EGA Director General, presents the generic
medicines industry's position on anti-counterfeiting policy at the
European Parliament, expressing strong support for Europe’s record
of protecting pharmaceutical supplies from counterfeiters.
PRESS RELEASE: 3 May 2007
BUILDING A “MARKET PATHWAY” FOR BIOSIMILAR MEDICINESNow that the science and the regulatory pathway have been established in the EU, industry and regulators must focus on building a “market pathway” for biosimilar medicines.
PRESS RELEASE: 13 February 2007
LACK OF AGENCY RESOURCES DELAYING GENERIC MEDICINES APPLICATIONSWhile praising EU regulators for the smooth implementation and running of the new Decentralised Procedure (DCP), the EGA is concerned about the serious lack of resources available to Member State agencies to deal with the regulatory workload.
The EGA
“In an era when increasing demands are being made on Europe’s healthcare services, generic medicines provide a major benefit to society as they ensure patient access to quality, safe and effective medicines while reducing the cost of medicinal care.”
The EGA is the official representative body of the European generic pharmaceuticals industry, which is at the forefront of providing high-quality affordable medicines to millions of Europeans while stimulating competitiveness and innovation in the pharmaceutical sector.
The EGA represents over 500 companies and their subsidiaries from greater Europe, and over 120,000 jobs. Generic medicines save €25 billion each year for health care systems and patients.
For further information:
About the EGA About Generics